Compounded Semaglutide in 2026: Is It Still Available After the FDA Ruling?
The Question Everyone Is Asking
Can you still get compounded semaglutide in 2026? The short answer: yes, through 503A compounding pharmacies — but the landscape has shifted significantly. Understanding what changed, what's still available, and which providers remain operational requires navigating an evolving regulatory environment.
503A vs. 503B: What's the Difference?
503A pharmacies compound medications based on individual patient prescriptions. They operate under state pharmacy board oversight and can compound when a prescriber determines a medical need exists for a specific patient. These pharmacies continue to prepare compounded semaglutide and tirzepatide.
503B outsourcing facilities compound larger batches without individual prescriptions. The FDA has moved to restrict 503B compounding of semaglutide and tirzepatide following the resolution of the original drug shortage that enabled compounding.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Prescription required? | Yes — individual patient Rx | No — bulk production |
| Oversight | State pharmacy board | FDA registered + inspected |
| Batch size | Individual patient quantities | Large commercial batches |
| Current semaglutide status | Available via patient Rx | Restricted by FDA |
| Price range | $99–350/month | Was $150–400/month |
What Changed and Why
Compounded semaglutide became widely available during the FDA-declared shortage of brand-name Wegovy and Ozempic. Federal law permits compounding of drugs on the shortage list. When Novo Nordisk increased production and the FDA determined the shortage was resolved, the legal basis for 503B compounding narrowed.
However, 503A compounding — based on individual patient prescriptions — operates under a different legal framework and is not contingent on shortage declarations. As long as a prescriber determines a legitimate medical need (such as specific dosing, different salt forms, or patient-specific formulations), 503A pharmacies can prepare compounded versions.
What It Costs Now
Compounded semaglutide through 503A pharmacies typically costs $99–350/month depending on the provider and dosage. Brand-name Wegovy lists at approximately $1,350/month without insurance. For men without GLP-1 coverage, the compounded option represents significant savings.
| Option | Monthly Cost | Insurance? | Availability |
|---|---|---|---|
| Brand-name Wegovy | $1,350+ | Sometimes covered | Pharmacies nationwide |
| Brand-name Ozempic (off-label) | $900+ | Diabetes indication only | Pharmacies nationwide |
| Compounded semaglutide (503A) | $99–350 | No | Via telehealth providers |
| Compounded tirzepatide (503A) | $133–400 | No | Via telehealth providers |
Providers Still Offering Compounded GLP-1s
Multiple telehealth providers continue to prescribe compounded semaglutide and tirzepatide through 503A pharmacy partnerships. Here are options currently active:
SkinnyRx
Compounded semaglutide and tirzepatide options.
SkinnyRx GLP-1 Programs →Ivim Health
GLP-1 weight loss programs with provider consultation.
Ivim Health →Care Bare Rx
Compounded GLP-1 options with personalized dosing.
Care Bare Rx →SHED
Compounded GLP-1 programs with titration support.
GobyMeds
Compounded semaglutide from $99/mo, tirzepatide from $133/mo. Use code x7X72r for $25 off. Also offers NAD+ and Sermorelin.
Get Started with GobyMeds →Frequently Asked Questions
Is compounded semaglutide safe?
Compounded semaglutide from state-licensed 503A pharmacies uses pharmaceutical-grade ingredients prepared under regulated conditions. However, compounded drugs do not undergo FDA approval review. Choose providers that work with USP <797>-compliant pharmacies.
Is it the same as Wegovy or Ozempic?
The active ingredient (semaglutide) is the same molecule. However, compounded formulations may use different salt forms (e.g., semaglutide sodium vs. semaglutide base) and have not been tested for bioequivalence with the branded products.
What if compounding becomes completely unavailable?
Brand-name options remain available. Insurance coverage is expanding. Patient assistance programs and manufacturer savings cards can reduce costs. Some providers also offer tirzepatide compounding as an alternative.
Should I switch to brand-name now?
If you have insurance coverage, brand-name may be worthwhile for FDA-oversight benefits. If cost is the primary factor, compounded options remain available through 503A pharmacies.